Mitchell D. Nambu

6 papers receiving 1.6k citations

Mitchell D. Nambu's Hit Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) 2011 · 811 citations
8110+6+12Years since publication250500750

Peers

Mitchell D. Nambu
Comparison fields: 5 of 63
  • Pulmonary and Respiratory Medicine 639
  • Computational Theory and Mathematics 239
  • Pathology and Forensic Medicine 216
  • Organic Chemistry 384
  • Hepatology 45
Replace Jean Cui with:
Jean Cui United States
Peiwen Yu United States
Timothy J. Guzi United States
Fawn Qian United States
Jens Quant Austria
Lyndon A. M. Cornelius United States
Steven Do China
Mason Pairish United States
Paula J. Kaplan‐Lefko United States
Claire Crafter United Kingdom
Mitchell D. Nambu relative to Jean Cui United States Jean Cui's profile →
Citations per field
00.5×1.5×2×2.5×
Jean Cui · 1×
Citations per year

Countries citing papers authored by Mitchell D. Nambu

Since Specialization
Citations

This map shows the geographic impact of Mitchell D. Nambu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell D. Nambu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell D. Nambu more than expected).

Fields of papers citing papers by Mitchell D. Nambu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell D. Nambu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell D. Nambu. The network helps show where Mitchell D. Nambu may publish in the future.

Co-authors

The 25 scholars most cited alongside Mitchell D. Nambu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mitchell D. Nambu Line = papers co-authored together Mitchell D. Nambu links everyone, so they are left out of the graph.

All Works

6 of 6 papers shown
#Work
1
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Hit paper breakdown →
2011811
2
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
Hit paper breakdown →
2007648
3 201295
4 201335
5 201030
6 201723

About Mitchell D. Nambu

Mitchell D. Nambu is a scholar working on Computational Theory and Mathematics, Pathology and Forensic Medicine, Organic Chemistry, Hepatology and Molecular Biology, having authored 6 papers that have together received 1.6k indexed citations. Recurring topics across this work include Synthesis and biological activity (2 papers), Cancer Mechanisms and Therapy (2 papers), Computational Drug Discovery Methods (2 papers), Synthesis and Characterization of Heterocyclic Compounds (2 papers), Lung Cancer Treatments and Mutations (1 paper), PI3K/AKT/mTOR signaling in cancer (1 paper), Antifungal resistance and susceptibility (1 paper) and Liver physiology and pathology (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (639 citations), Computational Theory and Mathematics (239 citations), Pathology and Forensic Medicine (216 citations), Organic Chemistry (384 citations) and Hepatology (45 citations). Mitchell D. Nambu has collaborated with scholars based in United States. Frequent co-authors include Helen Y. Zou, James G. Christensen, Shinji Yamazaki, Qiuhua Li, Barbara Mroczkowski, Maria E. Arango, Jingrong Jean Cui, Pei‐Pei Kung, Scott R. P. McDonnell and Gerrit Los. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact